PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2009.
“Our sales team delivered another solid quarter for us with record numbers of XYREM and LUVOX CR prescriptions and net sales” said Bob Myers, President of Jazz Pharmaceuticals.
Jazz Pharmaceuticals’ net loss for the third quarter of 2009 was $1.7 million, compared to a net loss of $28.8 million for the third quarter of 2008.
Jazz Pharmaceuticals will host an investor conference call and live audio webcast to give a company update, as well as to discuss financial results and guidance, today (November 5, 2009) commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.JazzPharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing 1-866-825-1692 in the U.S., or 1-617-213-8059 outside the U.S., and entering passcode 25459996.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.
CONTACT: Karen L. Bergman, +1-650-575-1509, or Michelle Corral,
+1-415-794-8662, both of BCC Partners on behalf of Jazz Pharmaceuticals,
Inc.; or Willie Quinn, Executive Director, Corporate Development of Jazz
Pharmaceuticals, Inc., investorinfo@jazzpharmaceuticals.com
Web site: http://www.jazzpharmaceuticals.com/
